Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label multicenter study of DF203 injection in malignant pleural effusion
CTR20260918Phase 2Active
- Sponsor
- Shihuida Pharmaceutical Group
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of DF203 in malignant pleural effusion (MPE), sponsored by Shihuida Pharmaceutical Group. Started May 2026; status: active.
02
Drugs
DF203
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on CTR20260918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260918.